On Monday, Aug. 21, beginning shortly after 9 a.m. Pacific Time, the sky will darken across North America as the moon’s orbit carries it between […]

The post Enrich your solar eclipse experience with this new app! appeared first on Smithsonian Insider.

Black holes sound wildly complicated. After all, there are all sorts of bizarre things going on: intense gravity, the warping of the fabric of space, the distortion of time itself. But when it comes to describing black holes, it comes down to just two numbers: the mass of the black hole and its spin. That’s right. Everything you physically need to describe a black hole is found in just these two numbers.

The post Black Holes, just two numbers is all you need… appeared first on Smithsonian Insider.

Here come the stinkbugs...With the cooler temperatures of fall the brown marmorated stinkbug begins a determined quest to find a warm place to spend the winter. Crowding around window screens and searching for other ways to get inside, homeowners in the United States will share their indoor living space this winter with millions of brown marmorated stinkbugs. In this video Gary Hevel, an entomolgist at the Smithsonian's National Museum of Natural History, shares some information about these interesting creatures, as well as some advice about how to deal with those that inevitably gain entry to your home.

The post Smithsonian entomologist Gary Hevel gives information and advice about stinkbugs in your home appeared first on Smithsonian Insider.

The post “How Soil Savvy are You?, is featured in the exhibition “Dig It! The Secrets of Soil,” from the Smithsonian Traveling Exhibition Service appeared first on Smithsonian Insider.

The post How do we know if dinosaurs cared for their young? Smithsonian curator Matthew Carrano reveals the fossil evidence. appeared first on Smithsonian Insider.

Smithsonian planetary geologists Sharon Purdy and Maria Banks explain how you can take your very own photo of Mars.

The post Scientists Maria Banks and Sharon Purdy explain how to take your own photo of Mars. appeared first on Smithsonian Insider.

The National Museum of Natural History in Washington, D.C., has closed its Dinosaur Hall for a five-year renovation. But before the overhaul can begin, the […]

The post How do you dismantle a dinosaur? appeared first on Smithsonian Insider.

Steven Young Lee blends Eastern and Western traditions with anachronistic, often playful imagery and striking pattern in his porcelain works. His process allows the clay […]

The post Steven Young Lee-Visions and Revisions: Renwick Invitational 2016 appeared first on Smithsonian Insider.

Get a quick tutorial on how to upload a story about your local culture and experiences to the Smithsonian’s storytelling website, located www.museumonmainstreet.org Museum on […]

The post Posting Your Story to Smithsonian’s Museum on Main Street Website appeared first on Smithsonian Insider.

An overview of the Smithsonian Affiliations program and its reach in communities across the United States. Is the Smithsonian in your neighborhood?

The post Smithsonian Affiliates in your neighborhood appeared first on Smithsonian Insider.

Why do we love orchids so much? Tom Mirenda, Smithsonian Gardens orchid collection specialist, believes it is partly because orchids seem to look back at […]

The post 5 Crazy Things You Didn’t Know About Orchids appeared first on Smithsonian Insider.

In the dark recesses of an underground fungus garden, a Panamanian leaf-cutting ant plucks a tuft of mycelia, the wispy part of the basidiomycete fungus […]

The post Mystery solved? Ants Protect Young From Infection By Cocooning Them in Fungus appeared first on Smithsonian Insider.

If you try to open a text file with UTF-16 or UTF-32 encoding, the Import Tool displays a warning message stating that the encoding is not supported.  If you continue to load the file anyways, it is opened with UTF-8 encoding, and the file may not be displayed or imported as expected.This bug exists in the following release(s):
R2020a

This bug has a workaround

Interested in Upgrading?

and change it if required.

For several versions of Windows

A still from "POWER/RANGERS," a highly-produced Power Rangers fan film starring James Van Der Beek and Katee Sackhoff.

Update 2/28: The "POWER/RANGERS" film is back on YouTube and Vimeo. Watch the censored YouTube version with a new viewer discretion disclaimer here:

POWER/RANGERS

You can also watch the Vimeo version, featuring more adult content. The video's description emphasizes its lack of connection in any official way to the Power Rangers:

"Deboot of the Power Rangers. My take on the FAN FILM. Not a pilot, not a series, not for profit, strictly for exhibition. This is a bootleg experiment not affiliated or endorsed by Saban Entertainment or Lionsgate nor is it selling any product. I claim no rights to any of the characters (don't send me any money, not kickstarted, this film is free). This is the NSFW version. An alternate safe version is on youtube."

Director Joseph Kahn tells Deadline, "They put these disclaimers on so kids so don’t confuse our super-violent film with their Power Rangers brand. There are no hard feelings. We signed contracts. We can play it anywhere we want on all platforms. I think they realized that people just want to see it."

Previously: A Power Rangers short film went viral this week, starring Katee Sackhoff (Battlestar Galactica) and James Van Der Beek (Dawson!) in a Tarantino-meets-sci-fi take on a dark future for the formerly Mighty Morphin'.

The company behind the 22-year history of the kids/toy icons issued takedown requests, leading to it being pulled from Vimeo and, on Thursday afternoon, a toned-down version being taken off YouTube. At the time, the video had received over 10 million views. It's still available to watch in this Facebook embed from the producer's Facebook page:

POWER/RANGERS Facebook embed

The film was directed by Joseph Kahn, best known as the music video director behind clips like Taylor Swift's "Blank Space" as well as videos for Britney Spears, U2 and others, and produced by Adi Shankar, who was also behind "The Grey" and "Dredd." Kahn co-wrote the film with Van Der Beek and lesser-known writer Dutch Southern.

This isn't the first quasi-legal fan film produced by Shankar. He's also done the same with Marvel Comics characters the Punisher and Venom. The Punisher film even had one of the actors who played the character on screen, Thomas Jane.

Watch those films (Warning: Adult language and violence):

Punisher short

Venom short

Kahn tells HitFix that Shankar came to him, offering him the chance to reboot an existing property.

One reason for the current legal contentiousness: The Power Rangers are set to hit the big screen next year in a Lionsgate film. Kahn says that, if that film was offered to him, he wouldn't be interested.

"I wouldn't even want to make 'Power Rangers: The Movie' for real," Kahn told HitFix. "Like if I had to make a 'Power Rangers' movie, this is it. It's 14 minutes long, and it's violent, and this is what I have in me. If they offered me the $200 million version, the PG-13 version, I literally wouldn't do it."

There's been a strong response to the video, but the response has been mixed — among the original Power Rangers. The original Green Ranger, actor Jason David Frank, said on Facebook that he was approached to be in the movie but declined. (The film's director denies this claim, saying that Frank must have confused them with another project.) Frank also criticized the adult content.

"I'm just a PG-13 guy," Frank said. "The cuss words, the drugs, all this other stuff, it doesn't fly with me." He says that he thinks the Power Rangers are still connected with kids, and he didn't like the idea of doing a dark and gritty version in that context. (Watch his video below.)

Green Ranger video

But the original Pink Ranger, actress Amy Jo Johnson, gave the film her stamp of approval, which Sackhoff enthusiastically responded to.

Amy Jo Johnson tweet 1

Amy Jo Johnson tweet 2

Katee Sackhoff tweet

Sackhoff told the Nerdcore Movement site that she loves fan films.

"Doing a fan video is kind of the biggest honor you can give a franchise. It’s something that inspired you so much that you want to create," Sackhoff said.

Kahn defended "POWER/RANGERS" on Twitter as being protected due to it being a satire and also cited fair use laws and free speech. He argued that there are lots of other fan films and pointed out that YouTube showed more leniency, leaving it up.

"Every image in POWER/RANGERS is original footage," Kahn wrote in a series of tweets to Vimeo. "Nothing was pre-existing. There is no copyrighted footage in the short."

He also said that it's being given away for free and that Kahn paid for it himself.

Kahn tweet

"It is just as if I drew a pic of Power Rangers on a napkin and I gave it to my friend," Kahn wrote. "Is it illegal to give pic I drew of a character on a napkin to someone for free? No. The world is watching your actions right now."

In a touch of irony, the video had been selected as a Vimeo staff pick before the service took it down. They also responded to complaints about it being taken down, saying that they had to due to the Digital Millennium Copyright Act, and that they would restore the video immediately if the copyright claim was withdrawn, telling fans to complain to Power Rangers copyright holder Saban.

YouTube tweet

Despite the short film's success, hardcore Power Rangers fans are less sure about it, Shamus Kelley tells KPCC. Kelley created his own Rangers fan series, as well as co-hosting a Power Rangers podcast with over 300 episodes so far.

Casual fans are "far more open to the idea of dark/gritty because they see it as the show growing up with them," Kelley says. To hardcore fans, "it was either an abomination or the greatest unintended parody ever."

Kahn tells HitFix that the parody, of both Power Rangers and fan films in general, is definitely intended.

"The dark and gritty reboot thing is such a cliché that the intention was not only to make it dark and gritty but make it even darker and grittier than you could possibly imagine, hence the brains, the blood and the violence and the sex," Kahn said.

Kahn is set to answer questions about the film in a Reddit AMA on Friday at 2 p.m. We'll have to wait and see if there will be anywhere to watch it at the time.

Take a look behind the scenes of "POWER/RANGERS" via posts from the director and stars:

Behind the scenes tweet

Behind the scenes Instagram

Fight training 1

Fight training 2

The film also includes a techno take on the classic Power Rangers theme song, which you can listen to here:

Techno Power Rangers

This story has been updated.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A cosplay gathering in the Anaheim Convention Center's Grand Plaza during WonderCon Anaheim 2014.; Credit: Kevin Green/SDCC

For all the sad comic book and pop culture fans who weren't able to get tickets to San Diego Comic-Con, we've got good news for you: They run another convention, and it's closer to Los Angeles. Their little brother WonderCon Anaheim has been growing, with some comparing it to the Comic-Con of old — before it got way too crowded. It's this Friday through Sunday, April 3-5. They're starting to have big stars and lots of great panels, so if you want to get your geek heart sated, here are some of the events you won't want to miss.

Warner Bros. Presentation: San Andreas, Mad Max: Fury Road

San Andreas trailer

The most highly anticipated event at this weekend's convention, Warner Brothers is putting on a special presentation with footage from these two upcoming action films. They haven't announced which stars will be on hand, but these panels often surprise with star power, so you may get a visit from stars like "San Andreas's" Dwayne "The Rock" Johnson or "Mad Max: Fury Road's" Tom Hardy or Charlize Theron. At the Comic-Con panel last year for the "Mad Max" flick, the director talked in detail about the film, so you'll probably at least get his take on the franchise and its resurrection.

DC Comics TV shows: The Flash, Gotham, iZombie

The Flash trailer

While Marvel has been dominant on the big screen, DC has put out a diverse slate of TV shows, with "The Flash" being the biggest hit among them. It's among those getting a spotlight at WonderCon, with creators and stars dishing on the programs that have captured the imaginations of TV fans and comic fans alike. All three shows are also getting special video presentations, likely showing clips of what you can expect the rest of this season. And in case you didn't already know, "iZombie" comes from "Veronica Mars" creator Rob Thomas, so come find out about his latest project.

World Premiere: Batman vs. Robin

Batman vs. Robin trailer

It's become a tradition at both WonderCon and San Diego Comic-Con for DC Comics to debut their latest animated movie, and the new one is based on the critically acclaimed "Court of Owls" storyline by writer Scott Snyder. (Be sure to check out our previous interviews with Snyder — he's even an NPR fan.) The original story is based on how Batman thinks he knows everything there is to know about Gotham City and faces the discovery that there are deep secrets about the city that he had no idea about, and the film also emphasizes him fighting his son Damian.

Sing-alongs: Dr. Horrible & Batman's The Music Meister

Batman: The Brave and the Bold: Drives Us Bats

People go to comic conventions to geek out, and what's geekier than a good old-fashioned singalong? In addition to one for geek god Joss Whedon's much loved Web series "Dr. Horrible's Sing-Along Blog," they're also doing one for the musical episode of animated series "Batman: The Brave and the Bold" — which, just like "Dr. Horrible," features singing by the one and only Neil Patrick Harris. In the Batman cartoon, he plays the Music Meister, a Batman villain who makes both heroes and villains sing, as he drops some tunes of his own.

Superman: The Richard Donner Years Celebrity Super Reunion

Superman: The flying sequence

There's a reunion of stars from the first two of the classic Christopher Reeve Superman movies, including Lois Lane herself, Margot Kidder. You can also see the actors who played characters like Jimmy Olsen, several of the villains and more, as well as two of the producers. Find out what you don't know about the movie that broke ground when it came to depicting flight on-screen and, like the ads promised, made you believe a man could fly.

TV writing panels

Two panels will give you a peek into the world of the writers who write some of the hottest shows on TV: "TV Guide Magazine's Fan Favorites Showrunners" and "Inside The Writers' Room: Earth's Mightiest Writers Re-Assemble Redux." The first of those includes legendary TV showrunners like Dan Harmon of "Community" and the minds behind shows including "Orphan Black," "The Goldbergs" and more. Meanwhile, at the writers room panel, you'll get writers who've worked on shows like "Lost," "Firefly," "Heroes," "The Big Bang Theory," "Agent Carter" and more.

Fan culture programming track

This includes a lot of different panels, but it's a sign of the way fandom is shifting — it's a lifestyle that's far more diverse than it used to be, with a lot more gender parity. This track includes panels on topics like body confidence in cosplay, fashion, fitness, race and more. See what sparks your interest and might invite you into having an identity as a fan being a bigger part of your life while not letting anyone make you feel excluded.

There's so much more, like Will Forte doing a panel promoting his new show "The Last Man On Earth," the annual cosplay masquerade and so much more. Tickets are sold out for Saturday, but at press time, tickets were still available for both Friday and Sunday at WonderCon.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Full Text:

Needle pricks not your thing? A team of National Science Foundation-funded scientists is developing wearable skin sensors that can detect what's in your sweat. They hope that one day, monitoring perspiration could bypass the need for more invasive procedures like blood draws, and provide real-time updates on health problems such as dehydration or fatigue. In a new paper, the team describes a new sensor design that can be rapidly manufactured using a "roll-to-roll" processing technique that essentially prints the sensors onto a sheet of plastic like words on a newspaper. They used the sensors to monitor the sweat rate, and the electrolytes and metabolites in sweat, from volunteers who were exercising, and others who were experiencing chemically induced perspiration. The new sensors contain a spiraling microscopic tube, or microfluidic, that wicks sweat from the skin. By tracking how fast the sweat moves through the microfluidic, the sensors can report how much a person is sweating, or their sweat rate. The microfluidics are also outfitted with chemical sensors that can detect concentrations of electrolytes like potassium and sodium, and metabolites like glucose.

Image credit: Bizen Maskey/Sunchon National University

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.